Introduction
Cancer develops from an individual cell that accumulates acquired mutations.
Appropriate medical care requires thorough understanding of the natural history of the disease, including the identification and order of occurrence of the mutations, the cell of origin and the clonal organization of the tumor cells. In addition, because the transformation process can capture pre-existing somatic mutations (1, 2) , their driver nature needs to be fully established, based on their recurrence and their functional consequences. Such in depth investigations identify initial driver mutations, which are relevant as targets for therapy.
Chronic lymphocytic leukemia (CLL), the most frequent adult leukemia in western countries, is an accumulation of mature B-lymphocytes (3) . The CLL tumor cells are clonal, based on the immunoglobulin heavy chain (IGH) gene rearrangement and express low levels of surface B-cell receptor. In a fraction of the patients, the IGHV rearrangement is mutated, reflecting normal somatic hyper mutation triggered by antigen recognition. The IGHV-mutated patients have a better prognosis than IGHVnon-mutated ones.
Investigation of CLL samples by massively parallel sequencing has identified numbers of acquired somatic mutations (4, 5) , but no individual gene is mutated in more than 20% of the patients. The products of the mutated genes are involved in RNA metabolism, genome stability and cell cycle, control of the Notch pathway, Wnt signaling and inflammation (4) . Transformation may also depend on specific IGH rearrangements and B-cell receptor intracellular signaling cascades (6, 7) . The cell of origin of CLL is currently debated. Immunophenotype and expression profiles analyses pointed at mature CD5 + B-cells (8) , but the involvement of early hematopoietic cells in CLL development has been revitalized following xenograft
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Author Manuscript Published OnlineFirst on June 11, 2014; DOI: 10.1158/2159-8290.CD- experiments: the hematopoietic stem/progenitor cells from CLL patients show biased and abnormal differentiation toward the B-lymphoid lineage in immunodeficient mice. (9) To investigate the natural history of CLL, we embarked in a thorough analysis of CLL samples using massive parallel sequencing and cellular analyses.
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RESULTS

SF3B1 mutations are detected in non-lymphocytic cellular fractions of CLL patients
To search for CLL mutations in the hematopoietic progenitor cell fraction, we first investigated the distribution of SF3B1 mutations in the hematopoietic tree of SF3B1-mutated CLL patients since this gene is frequently mutated in both CLL and myelodysplastic syndrome (MDS), a chronic stem cell-derived myeloid tumor (10, 11) . Sanger sequencing of the mutational hotspots of the SF3B1 gene on DNA from 50 CLL patients identified 7 patients carrying a SF3B1 mutation. We next flow-sorted cells according to the expression of mutually exclusive cell surface markers: CD34 (which marks the immature progenitor cells compartment at the apex of hematopoietic differentiation), and markers of mature cells, CD3 (T-cell), CD14
(monocytes) and CD19 (both normal and tumor B-cells). Sequencing analyses of DNA from these cellular fractions showed wild type SF3B1 sequences in the CD3 + and the mutated sequence in the CD19 fraction, in all seven cases. The mutation was also observed in CD34 + and/or CD14 + fractions in two of them ( Supplementary   Fig. S1 ), suggesting it was acquired, in these patients, in an early progenitor, able to participate in both lymphoid and myeloid differentiation.
Acquired mutations are detected in multipotent progenitors in the majority of CLL patients.
We next used whole-exome sequencing of DNA from flow-sorted cell populations of 24 CLL patients (17 IGHV-unmutated and 7 IGHV-mutated, Supplementary Table S1 and Fig. 1A ). Some mutations were present in virtually all the CD19-positive cells, whereas the allelic ratio of other mutations indicated that they were present only in a fraction of them, indicating they were secondarily acquired.
We used targeted deep resequencing to simultaneously validate and quantify the mutation burden in DNA from the sorted fractions ( did not show mutated colonies (Fig. 1B and supplementary Table S1 ). Although the absence of mutation may be due to the low number of colonies in some patients (as for patient CLL08), the other 4 patients clearly did not show mutated cells in over 50 colonies analyzed. In addition, the frequency of mutated colonies differed from the estimated mutation burden in the sorted CD34 + fractions, supporting the idea that not all mutated progenitors could grow in these myeloid culture conditions. We also investigated the myeloid colonies from 17 patients for the presence of the CLL IGH rearrangement using rearrangement-specific PCR. No IGH-rearranged colonies were detected for 11 patients (CLL01, 02, 03, 08, 09, 11, 12, 13, 16, 20, 26 Together, these data demonstrate the presence of CLL-mutations in a multipotent Table S1 ).
The early mutations affect genes recurrently mutated in CLL and other malignancies
Mutations detected in the progenitors of CLL patients affected genes already known to be mutated in CLL, other hematological malignancies, or even in other cancers, supporting their active role in transformation (Supplementary Table S2 ).
Early mutations were observed in the NOTCH1, SF3B1, TP53, and XPO1 genes that belong to the most frequent mutated ones in CLL (4, 5, 12) . Genes such as BRAF or MLL2 are mutated in CLL and in other B-cell malignancies (13) (14) (15) . A few EGR2 and NFKBIE mutated patients have been reported in CLL (4, 5, 16 months; p= 0.04) (Fig. 2D ).
Deregulation of BCR signaling as a phenotypic convergence of early mutations in CLL
Normal BCR and pre-BCR signaling occurs through BRAF, which activates ERK proteins (18) , which in turn phosphorylate and activate the Ternary Complex
Factor-SRF dimer resulting in the up regulation of a set of immediate early genes, including EGR2 (19, 20) . BRAF and EGR2 mutations may therefore impact on the BCR signaling, which is abnormal in CLL (7). BRAF mutations, most frequently V600E, have been described in a variety of human malignancies, including hairy cell leukemia (13, 21) , another malignant B-cell disease. In CLL, BRAF mutations rather target amino acids located in the P-loop of the kinase (Supplementary Table S4 and (22)) leading to weaker activation than the canonical V600E mutations (18) . Ectopic expression of the CLL-mutant BRAF-G469R in Ba/F3 cells showed a constitutive ERK phosphorylation and Egr2 transcription ( We next investigated the consequences of EGR2 mutations. The EGR2 gene encodes a versatile transcription factor that participates in the control of cellular differentiation, including myeloid (23), B-and T-lymphoid differentiation (24, 25) . All EGR2 mutations identified in CLL were heterozygous missense mutations, and, with the exception of R426Q, were located within the zinc finger domains (Fig. 2C ). In addition, EGR2 mutations were detected as early molecular events in two patients (CLL12 and CLL22; Fig. 1B and Supplementary Table S1 ).
To investigate the functional consequences of EGR2 mutations, we first expressed GST-fusion proteins including the zinc-finger region of wildtype or two EGR2 mutants (E356K and H384N). Electromobility shift analyses using a biotinylated probe corresponding to a high affinity EGR2-site (26) showed specific binding of the WT and the H384N proteins ( Fig. 4A ), although H384N binding appears weaker than wildtype despite comparable protein amounts (Fig. 4B ). The interaction of the E356K protein with the probe was not observed in this assay. To investigate their transcriptional regulation properties, we expressed the wild type and the mutant forms of EGR2 in the murine multipotent hematopoietic cell line EML.
Expression levels of all EGR2 isoforms were comparable ( Fig. 4C ) and associated with a slower growth (Fig. 4E ). Cells expressing wildtype EGR2 showed a progressive reduction in the expression of the cell surface markers B220 (Blymphoid) and Gr1 (myeloid) (Fig. 4D ). Growth slow-down and loss of B220 + and
Gr1
+ cells was even faster in cells expressing mutant EGR2 ( Fig. 4D and E) indicating that the mutations had a functional impact. We investigated the expression of known EGR2 target genes using RNA obtained from sorted GFP+ cells, 3 days after transduction, to detect primary transcriptional changes induced by EGR2 expression. As shown Fig. 4F , wild type and mutated EGR2 proteins interfered with the expression of EGR2 targets. The effects of the three EGR2 proteins were similar on Csf1 transcription, whereas WT-EGR2 was stronger than E356K, which was stronger than H384N in the transactivation of Gadd45b. Taken together, these results indicate that the EGR2 mutations in CLL do not functionally inactivate the protein but rather affect the transcription of EGR2-target genes. Whereas the differential activities of the mutants is due to differences in EGR2 binding site or interaction with transcription co-factors at the target genes will require additional investigations.
To investigate the functional consequences of EGR2 mutations in patient samples, we analyzed RNA-seq data obtained from 16 CLL samples. Fifteen genes were down regulated, whereas 224 genes were specifically up regulated in EGR2-E356K samples (n=4) as compared to EGR2 wild type or unanalyzed patients (n=10; p<0,01; Supplementary Table S5) . Hierarchical clustering using the 224 up regulated genes showed clustering of all 5 EGR2 mutated CLL samples, including the EGR2-H384R sample (Fig. 5A ). An additional sample, which was not analyzed by exome sequencing and lacked acquired mutation in EGR2, clustered together with the EGR2-mutated samples, suggesting that other alterations mimic the effect of EGR2 mutations. To investigate whether the differentially expressed genes might be direct EGR2 targets, we used ChIP-seq data obtained using anti-EGR2 antibodieschromatin immunoprecipitation (27) from primary human monocytes extracts. Peaks
Research. (28) to identify 24 predicted EGR2-target genes using ARACne (see material and methods and Supplementary Table S6) . When used as a surrogate marker of EGR2 transcriptional activity, this signature showed transcriptional activity in EGR2-mutated samples (Fig. 5B) . Together, these data confirm that expression of mutated EGR2 proteins interferes with the expression of EGR2-target genes in vivo.
Since EGR2 is downstream of normal BCR signaling, we next determined a BCR-signaling signature. In that purpose, we defined a set of genes up regulated upon BCR-stimulation of normal B-cells, using available data (29, 30) and used GSEA analyses to show that this signature is enriched in EGR2-mutated samples, with respect to non-mutated samples ( Fig. 5C and D) . Reciprocally, the EGR2-E356K-signature was markedly enriched in BCR-stimulated samples, when compared with unstimulated B-cells ( Fig. 5E and F) , further establishing the deregulation of intracellular BCR signaling in EGR2-mutated samples.
DISCUSSION
Here we identified acquired mutations in the hematopoietic progenitors of CLL patients and provided proof of principle for the role of these mutations during the natural history of the disease.
Our data identified early-mutated genes in CLL patients. The high mutation burden observed in some patients, in the progenitor and/or mature myeloid fractions underscores that the identified mutations are functionally relevant and lead to accumulation of mutated cells, in the progenitor and/or mature fractions. Some of those early drivers are well-known CLL oncogenes (i.e. NOTCH1, XPO1, SF3B1).
We also identified recurrent inactivating mutations of the NFKBIE gene in 10% of the patients and as an early event in one patient. NFKBIE encodes an inhibitor of NFKB activity, with a specific role in B-lymphocyte biology (31) (32) (33) . In addition, we show that acquired missense mutations of the EGR2 transcription factor are associated with a negative prognostic impact on patients' outcome and occur as an early event in two CLL patients.
Our functional data and global expression analyses also point at a common functional consequences of several mutations found in human CLL. EGR2 mutations alter transcriptional regulation activity of the protein, differently between mutants. A similar variability has also been observed for the EGR2 mutants observed in congenital neuropathies (34, 35) . EGR2 is a downstream target of the BCR and pre-BCR complexes, through an intracellular signaling cascade involving BRAF, ERK, ELK-SRF and finally EGR2 transcription upregulation (19) . Egr2 plays an important role in the fine-tuning of early B-cell differentiation (19, 24, 36, 37) 
signaling, and EGR2 deregulation, are observed in CLL (7, 30, 38) and our observations provide a molecular ground for these observations. We have not been able to investigate the involvement of the progenitor fractions in our series of patient.
In a different patient, relapsing from allograft treatment, we have detected an acquired SF3B1 mutation in the lymphoid primed multipotent progenitor (defined by expression of CD34+/CD38-/CD45RA+/CD90-(39)) fraction of a patient suffering from relapsed CLL (Supplementary Fig. S3B ). Together with the previous report of differentiation bias of CLL progenitor cells in xenograft experiments (9), our results suggest that abnormalities in hematopoietic progenitors and early B-cell differentiation is an early step during CLL pathogenesis. They also support the hypothesis that early CLL mutations, despite their diversity, show a convergent phenotype, through the impairment of B-cell differentiation, upon deregulation of (pre)BCR signaling. CLL would then develop from progenitors undergoing aberrant B-cell differentiation.
Finally, the diverse early CLL mutations may all induce a pre-leukemic stage devoid of overt clinical signs, conceptually similar to the one proposed for acute leukemia or observed in chronic myeloid neoplasms (1, 2). These observations may therefore have an impact on the follow-up and treatment of patients with CLL. It will therefore be important to understand how these findings relate to the clinical evolution of the patients and to what extent they also apply to other mature lymphoid malignancies (40) (41) (42) (43) .
METHODS
Statistical analysis
Clinical and laboratory variables were compared across patients with or without mutation using Wilcoxon rank sum test (for quantitative variables) or Fisher's exact test (for qualitative variables). Time to treatment was defined as time between diagnosis and first treatment and compared across groups using the Wilcoxon rank sum test. Overall survival was defined as survival since study enrollment; KaplanMeier estimator was used and survival curves were compared using the log-rank test. All tests were two-sided, with P value less than 0.05 considered as statistically significant. The SAS 9.3 (SAS, Inc., NC, USA) and R 3.0.2 (R Development Core Team, 2006) software packages were used.
Exome sequence analyses
We used sorted tumor CD19+ cells (and CD5+ when appropriate) and non-tumor (CD3+) cells to extract DNA for exome capture with the SureSelect V4 Mb All Exon kit (Agilent Technologies) following standard protocols. We performed paired-end sequencing (100 bp) using HiSeq2000 sequencing instruments at IGR or Tokyo. We mapped reads to the reference genome hg19 using the Burrows-Wheeler Aligner (BWA) alignment tool version 0.5.9. PCR duplicates were removed using Briefly, the number of the reads containing single nucleotide variations (SNVs) and indels in both tumor and reference samples was enumerated using samtools and the null hypothesis of equal allele frequencies between tumor and reference was tested using the two-tailed Fisher's exact test. For candidate somatic mutations, those variants were adopted as candidate mutations, whose p value was < 0.01 and allele frequency was < 0.1 in reference sample. Finally, the list of candidate somatic mutations was generated by excluding synonymous SNVs and other variants registered in either dbSNP131 (http://www.ncbi.nlm.nih.gov/projects/SNP/) or inhouse SNP database constructed from 180 individual samples (Genomon-exome:
http://genomon.hgc.jp/exome/en/index.html) as previously described (44) .
RNA Sequencing, mapping, and identification of differentially expressed genes.
RNA was extracted from flow-sorted CD19+ fraction using Qiagen columns, based on material availability. The cDNA libraries were prepared using the ScriptSeq Complete Kit (Epicentre). We performed paired-end sequencing as described for exome analysis. We removed ribosomal RNA reads (average 2,11 % of total reads) using alignment to the GenBank database. We removed low quality bases and adapters using Trimmomatic version 0.32. The remaining paired reads were mapped to the human reference genome hg19 using Tophat aligner version 2.0.9. The mapped reads were sorted according to their name using Samtools version 0.1.18.
We use the HTSeq python library version 0.5.4p5 to count the number of reads per gene using the gtf annotation file from UCSC (hg19) (45) . Genes with no count in all the samples were discarded and technical replicates were summed. Read numbers and normalization was performed using DESeq version 1.14.0 in the R environment version 3.0.2. To test for differential expression between EGR2 wild type (10 samples) and EGR2-E356K (4 samples), we used the R package DESeq with negative binomial distribution and a shrinkage estimator for the distribution's variance. P-values (adjusted by Benjamini and Hochberg procedure) lower than 1x10 -2 and fold changes higher than 2 were considered significant. Genes located on sex chromosomes were not considered.
GSEA analysis.
The CEL files of the GSE39411 (30) and GSE22762 (28) Table S5 ) between samples with and without an EGR2-E356K with the log2 expression of IGM-stimulated and unstimulated normal B-cells at 90 minutes.
EGR2 activity level.
EGR2 targets were predicted using the reverse-engineering algorithm ARACNe (46) (adaptive partitioning, 100 bootstraps, p<1e-9) using CLL expression profiles from
on GSE22762 (28) . EGR2 targets were used to compute the activity of the transcription factor across samples. For that, we first defined activated and repressed targets of EGR2 using the Spearman correlation sign between EGR2 and each target using the GSE22762 data set. The RNASeq-CLL gene expression profiles were centred and scaled so that each gene in order to define a comparable rank of expression of each gene across samples. Then for each independent sample, we can compute the activity level of EGR2 defined as the enrichment score (ES), as defined in GSEA 
Mutational analyses in 168 CLL patients.
Genomic DNA was extracted from peripheral blood mononuclear cells collected at time point of study enrollment using the DNA/RNA Kit (Qiagen) and amplified using the REPLI-G Kit (Qiagen). Genomic regions of BRAF (exons 11, 12, and 15), EGR2
on (48).
Flow cytometry and cell sorting or cloning.
Peripheral blood samples were stained with FITC anti-CD3, APC anti-CD14, PerCPCy5.5 anti-CD5, PE-Cy7 anti-CD19 and PE anti-CD34 all from BD Pharmigen, Inc.
For patients with sufficient available material, additional fractions using FITC antiCD56, PE anti-Igĸ and APC anti-Igλ were collected. A representative flow chart of the sorting procedure is shown in Supplementary Fig. S1 . CD34
+ were sorted as CD34 + CD19 -and were then cloned at one cell per well in 96-well plates ( Supplementary Fig. S1 ). Single-cell culture of CD34 + clones was performed for 10- 
1 IU/mL, Amgen, Inc.) and granulocyte colony-stimulating factor (G-CSF,10 ng/mL, Amgen). (41) Targeted resequencing and mutation validation.
Sorted cell fractions were subjected to DNA/RNA extraction using the All Prep DNA/RNA Kit (Qiagen) according to the manufacturer's recommendations. We designed primers flanking exons containing candidate somatic variants using Primer3 
Colonies genotyping.
DNA from CD34
+ colonies was prepared as described (49) . Mutational status and VJ rearrangement was analyzed by Sanger sequencing. The complete list of primers will be provided upon request.
Cellular methods
The IL3-dependent Ba/F3 cell line (from ATCC) is a kind gift of P Dubreuil (Marseille, France) ; the SCF dependent cell line EML is a kind gift of Guy Mouchiroud (Lyon, France). Cells were repeatedly tested for their growth factor-dependency and checked to be from murine origin by FACS. EML cells were grown in IMDM medium, 20% horse serum, 1% Penicilin/Streptomycine/Glutamine and supplemented with 10% of BHK cells supernatant. BaF3 cells were growth in RPMI medium, 10% bovine serum, 1% Penicilin/Streptomycine/Glutamine and supplemented with 10 ng/mL Il-3.
Retroviruses were produced and transduction performed as described (50) .
Growth curve
Twelve hours after transduction cells are washed, and seeded at 5 10 6 cells per well.
Cells were counted and analyzed by flow cytometry every 2 days. PE conjugated antibodies were Gr1 (RB6-8C5), B220 (RA3-6B2) from eBiosciences and Kit CD117 (2B8) from BD Pharmigen. Experiments were done at least twice in triplicate.
Electromobility shift assays (EMSA)
The cDNA portion of EGR2, encoding Zinc Finger domain (AA 1-2), was amplified by PCR and cloned into PGEX vector (GE Healthcare Life Sciences). Protein production was induced by IPTG stimulation and the fusion proteins purified using GlutathioneSepharose beads, and eluted from the beads with reduced glutathione following the manufacturer instructions. SDS-PAGE gel migration followed by Coomassie blue staining and image scanning was used for qualitative and quantitative assessment. The following Taqman probes were purchased from Applied Biosystems: Abl1:
Mm0065672_m1, Dtx1 Mm00492297_m1, EGR2 Mm00456650_m1.
Retroviruses
All cDNAs (EGR2: NM_001136177; BRAF: NM_004333) were subcloned into MSCV-GFP backbone. Mutations were introduced using quick change kit, following the manufacturer instructions. Every PCR-amplified or mutagenized fragment was checked by sequencing. Viral particles and transduction procedures were as described (50) .
Bone marrow transplantation assays and hematopoietic differentiation analyses were performed as described (41) 
